JP5604631B2 - 鉄関連眼病障害の治療および予防へのデフェリプロンの使用 - Google Patents
鉄関連眼病障害の治療および予防へのデフェリプロンの使用 Download PDFInfo
- Publication number
- JP5604631B2 JP5604631B2 JP2011546542A JP2011546542A JP5604631B2 JP 5604631 B2 JP5604631 B2 JP 5604631B2 JP 2011546542 A JP2011546542 A JP 2011546542A JP 2011546542 A JP2011546542 A JP 2011546542A JP 5604631 B2 JP5604631 B2 JP 5604631B2
- Authority
- JP
- Japan
- Prior art keywords
- iron
- deferiprone
- unit
- eye
- retinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims description 251
- 229910052742 iron Inorganic materials 0.000 title claims description 126
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 title claims description 98
- 229960003266 deferiprone Drugs 0.000 title claims description 98
- 208000030533 eye disease Diseases 0.000 title claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 29
- 230000002265 prevention Effects 0.000 title description 9
- 230000006378 damage Effects 0.000 claims description 47
- 210000001525 retina Anatomy 0.000 claims description 35
- 208000035475 disorder Diseases 0.000 claims description 24
- 208000010412 Glaucoma Diseases 0.000 claims description 17
- 208000002177 Cataract Diseases 0.000 claims description 16
- 206010038848 Retinal detachment Diseases 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 230000004264 retinal detachment Effects 0.000 claims description 15
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 14
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims description 14
- 238000011200 topical administration Methods 0.000 claims description 14
- 208000003435 Optic Neuritis Diseases 0.000 claims description 13
- 208000030768 Optic nerve injury Diseases 0.000 claims description 13
- 208000017442 Retinal disease Diseases 0.000 claims description 13
- 206010038923 Retinopathy Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 210000001927 retinal artery Anatomy 0.000 claims description 13
- 206010038831 Retinal artery thrombosis Diseases 0.000 claims description 12
- 206010047249 Venous thrombosis Diseases 0.000 claims description 12
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 11
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 11
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 11
- 230000000302 ischemic effect Effects 0.000 claims description 11
- 210000004204 blood vessel Anatomy 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 description 71
- 208000002780 macular degeneration Diseases 0.000 description 71
- 206010064930 age-related macular degeneration Diseases 0.000 description 58
- 238000000034 method Methods 0.000 description 52
- 241000699670 Mus sp. Species 0.000 description 50
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000003889 eye drop Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000002207 retinal effect Effects 0.000 description 11
- 102000007238 Transferrin Receptors Human genes 0.000 description 10
- 108010033576 Transferrin Receptors Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 8
- 229940012356 eye drops Drugs 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000036542 oxidative stress Effects 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 101150018634 Heph gene Proteins 0.000 description 7
- 206010025421 Macule Diseases 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010065973 Iron Overload Diseases 0.000 description 6
- 201000007737 Retinal degeneration Diseases 0.000 description 6
- 239000002738 chelating agent Substances 0.000 description 6
- 210000003161 choroid Anatomy 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 230000003449 preventive effect Effects 0.000 description 6
- 230000004258 retinal degeneration Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 108091008695 photoreceptors Proteins 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 201000004569 Blindness Diseases 0.000 description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000009736 wetting Methods 0.000 description 4
- 206010003591 Ataxia Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010057430 Retinal injury Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000005980 beta thalassemia Diseases 0.000 description 3
- 208000022806 beta-thalassemia major Diseases 0.000 description 3
- 238000005842 biochemical reaction Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- VBIZUNYMJSPHBH-OQLLNIDSSA-N salinazid Chemical compound OC1=CC=CC=C1\C=N\NC(=O)C1=CC=NC=C1 VBIZUNYMJSPHBH-OQLLNIDSSA-N 0.000 description 3
- 229950007671 salinazid Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 108091006975 Iron transporters Proteins 0.000 description 2
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 2
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 2
- 206010061323 Optic neuropathy Diseases 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- BQYIXOPJPLGCRZ-REZTVBANSA-N chembl103111 Chemical compound CC1=NC=C(CO)C(\C=N\NC(=O)C=2C=CN=CC=2)=C1O BQYIXOPJPLGCRZ-REZTVBANSA-N 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 229960000958 deferoxamine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 231100000040 eye damage Toxicity 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 208000020911 optic nerve disease Diseases 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 206010010996 Corneal degeneration Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700000224 Familial apoceruloplasmin deficiency Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical class [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 208000008069 Geographic Atrophy Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010047555 Visual field defect Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000004300 dark adaptation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229940020947 fluorescein sodium Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14724509P | 2009-01-26 | 2009-01-26 | |
| US61/147,245 | 2009-01-26 | ||
| PCT/CA2009/001639 WO2010083582A1 (en) | 2009-01-26 | 2009-11-12 | Use of deferiprone for treatment and prevention of iron-related eye disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012515725A JP2012515725A (ja) | 2012-07-12 |
| JP2012515725A5 JP2012515725A5 (enExample) | 2012-12-06 |
| JP5604631B2 true JP5604631B2 (ja) | 2014-10-08 |
Family
ID=42355449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546542A Expired - Fee Related JP5604631B2 (ja) | 2009-01-26 | 2009-11-12 | 鉄関連眼病障害の治療および予防へのデフェリプロンの使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130023569A1 (enExample) |
| EP (1) | EP2389179A4 (enExample) |
| JP (1) | JP5604631B2 (enExample) |
| KR (1) | KR20120078667A (enExample) |
| CN (1) | CN102348456A (enExample) |
| AP (1) | AP2011005843A0 (enExample) |
| AU (1) | AU2009338093B2 (enExample) |
| BR (1) | BRPI0920492A2 (enExample) |
| CA (1) | CA2750599A1 (enExample) |
| CL (1) | CL2011001812A1 (enExample) |
| CR (1) | CR20110456A (enExample) |
| EA (1) | EA201170970A1 (enExample) |
| IL (1) | IL214291A (enExample) |
| MA (1) | MA33090B1 (enExample) |
| MX (1) | MX2011007947A (enExample) |
| MY (1) | MY161269A (enExample) |
| NI (1) | NI201100148A (enExample) |
| NZ (1) | NZ594728A (enExample) |
| PE (1) | PE20120515A1 (enExample) |
| SG (1) | SG173145A1 (enExample) |
| TN (1) | TN2011000366A1 (enExample) |
| UA (1) | UA103366C2 (enExample) |
| WO (1) | WO2010083582A1 (enExample) |
| ZA (1) | ZA201105514B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016205030B2 (en) * | 2015-01-09 | 2021-04-01 | The Board Of Trustees Of The University Of Illinois | Restoring physiology in iron-deficient organisms using small molecules |
| CN111918646B (zh) | 2017-10-25 | 2022-02-22 | 奇斯药制品公司 | 延迟释放去铁酮片剂及其使用方法 |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046219A (en) * | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
| US5674888A (en) * | 1995-06-07 | 1997-10-07 | University Of California | Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
| AUPQ262499A0 (en) * | 1999-09-02 | 1999-09-23 | University Of Queensland, The | Novel iron chelators |
| WO2004041151A2 (en) * | 2002-11-07 | 2004-05-21 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| EP1601367A2 (en) * | 2003-02-06 | 2005-12-07 | Bioresponse L.L.C. | The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions |
| DK1991225T3 (da) * | 2006-02-22 | 2013-12-16 | Apotex Technologies Inc | Anvendelse af deferipron og fremgangsmåder til at behandle og/eller forebygge Friedreichs ataksi, der resulterer af intracellulær fejlhåndtering af jern |
| JP5290147B2 (ja) | 2006-04-14 | 2013-09-18 | プラナ バイオテクノロジー リミティッド | 加齢黄斑変性症（ａｍｄ）の処置方法 |
| ITMI20061770A1 (it) * | 2006-09-18 | 2008-03-19 | Carlo Ghisalberti | Metodo cosmetico di riduzione delle occhiaie |
| US8501789B2 (en) * | 2007-01-19 | 2013-08-06 | The Trustees Of The University Of Pennsylvania | Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease |
-
2009
- 2009-11-12 JP JP2011546542A patent/JP5604631B2/ja not_active Expired - Fee Related
- 2009-11-12 MY MYPI2011003478A patent/MY161269A/en unknown
- 2009-11-12 SG SG2011053972A patent/SG173145A1/en unknown
- 2009-11-12 UA UAA201110546A patent/UA103366C2/ru unknown
- 2009-11-12 CN CN2009801579837A patent/CN102348456A/zh active Pending
- 2009-11-12 EP EP09838587A patent/EP2389179A4/en not_active Withdrawn
- 2009-11-12 WO PCT/CA2009/001639 patent/WO2010083582A1/en not_active Ceased
- 2009-11-12 BR BRPI0920492A patent/BRPI0920492A2/pt not_active IP Right Cessation
- 2009-11-12 PE PE2011001408A patent/PE20120515A1/es not_active Application Discontinuation
- 2009-11-12 AU AU2009338093A patent/AU2009338093B2/en not_active Ceased
- 2009-11-12 AP AP2011005843A patent/AP2011005843A0/xx unknown
- 2009-11-12 EA EA201170970A patent/EA201170970A1/ru unknown
- 2009-11-12 US US13/138,263 patent/US20130023569A1/en not_active Abandoned
- 2009-11-12 NZ NZ594728A patent/NZ594728A/xx unknown
- 2009-11-12 MX MX2011007947A patent/MX2011007947A/es not_active Application Discontinuation
- 2009-11-12 MA MA34119A patent/MA33090B1/fr unknown
- 2009-11-12 CA CA2750599A patent/CA2750599A1/en not_active Abandoned
- 2009-11-12 KR KR1020117019874A patent/KR20120078667A/ko not_active Withdrawn
-
2011
- 2011-07-26 ZA ZA2011/05514A patent/ZA201105514B/en unknown
- 2011-07-26 TN TN2011000366A patent/TN2011000366A1/fr unknown
- 2011-07-26 CL CL2011001812A patent/CL2011001812A1/es unknown
- 2011-07-26 NI NI201100148A patent/NI201100148A/es unknown
- 2011-07-26 IL IL214291A patent/IL214291A/en not_active IP Right Cessation
- 2011-08-24 CR CR20110456A patent/CR20110456A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201170970A1 (ru) | 2012-03-30 |
| MA33090B1 (fr) | 2012-03-01 |
| NI201100148A (es) | 2012-03-06 |
| BRPI0920492A2 (pt) | 2019-07-09 |
| UA103366C2 (ru) | 2013-10-10 |
| AU2009338093A1 (en) | 2011-09-08 |
| EP2389179A1 (en) | 2011-11-30 |
| AU2009338093B2 (en) | 2014-08-28 |
| JP2012515725A (ja) | 2012-07-12 |
| MY161269A (en) | 2017-04-14 |
| TN2011000366A1 (en) | 2013-03-27 |
| EP2389179A4 (en) | 2012-08-29 |
| SG173145A1 (en) | 2011-08-29 |
| MX2011007947A (es) | 2011-12-14 |
| NZ594728A (en) | 2013-03-28 |
| AP2011005843A0 (en) | 2011-08-31 |
| CR20110456A (es) | 2012-05-31 |
| PE20120515A1 (es) | 2012-05-20 |
| WO2010083582A1 (en) | 2010-07-29 |
| IL214291A (en) | 2015-03-31 |
| CA2750599A1 (en) | 2010-07-29 |
| US20130023569A1 (en) | 2013-01-24 |
| IL214291A0 (en) | 2011-09-27 |
| CL2011001812A1 (es) | 2012-02-03 |
| CN102348456A (zh) | 2012-02-08 |
| KR20120078667A (ko) | 2012-07-10 |
| ZA201105514B (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aihara et al. | Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the phase 3 AYAME study | |
| AU2009240470B2 (en) | Inhibition of neovascularization by cerium oxide nanoparticles | |
| WO2003039404A2 (en) | Methods for treating ocular neovascular diseases | |
| RU2602738C2 (ru) | Комбинация фолиевой кислоты и рамиприла: цитопротекторные, нейропротекторные и ретинопротекторные офтальмологические композиции | |
| Abadia et al. | Clinical applications of dexamethasone for aged eyes | |
| EP3808352A1 (en) | Use of salidroside and derivative thereof in preparation of inhibitor medicament for diseases of ophthalmic fibrosis caused by abnormalities of extracellular matrix proteins | |
| JP5604631B2 (ja) | 鉄関連眼病障害の治療および予防へのデフェリプロンの使用 | |
| JP2012515725A5 (enExample) | ||
| KR20150126021A (ko) | 다이피리다몰을 이용하여 눈 장애를 치료하는데 사용하기 위한 조성물 | |
| JP2021512847A (ja) | キレート剤、浸透促進剤およびヒドロキシエチルセルロースを含む眼科疾患治療用製剤 | |
| ES2860767T3 (es) | Mirabegrón para el tratamiento de enfermedades retinianas | |
| CN116133641A (zh) | 胱氨酸贮积症的治疗 | |
| ZA200510344B (en) | Coumarin derivatives for the treatment of ophthalmic disorders | |
| EP3380194B1 (en) | Composition for blocking angiogenesis | |
| JP2009501725A (ja) | 糖尿病の眼科合併症の予防及び治療 | |
| JP2004323486A (ja) | 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬 | |
| ES2886723A1 (es) | Composicion basada en la actividad antioxidante de la enzima superoxido dismutasa y su aplicacion en enfermedades oculares | |
| HK1167244A (en) | Use of deferiprone for treatment and prevention of iron-related eye disorders | |
| US20240058308A1 (en) | Treatment and prevention of dry macular degeneration | |
| KR102879076B1 (ko) | Sglt-2 억제제를 포함하는 당뇨병성 안질환 예방 또는 치료용 약학적 조성물 | |
| US20240269115A1 (en) | Pyrazolone compounds for use in degenerative retinal diseases | |
| JP6764233B2 (ja) | 眼疾患処置薬 | |
| RU2192261C2 (ru) | Средство консервативного лечения прогрессирующей и осложненной близорукости | |
| US9308165B2 (en) | Composition for treating ocular effects of diabetes | |
| JP2024531861A (ja) | Ｓｇｌｔ－２阻害剤を含む糖尿病性眼疾患の予防または治療用薬学的組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121018 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121018 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140314 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140617 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140717 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140729 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140729 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140730 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5604631 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |